Program
Session recordings are available here.
The abstracts and the author index are now available in Brain Connectivity volume 11, issue 1. They will be available freely online through May 22.
PROGRAM AT-A-GLANCE
All times reflected below are in US Eastern Time zone.
MONDAY, OCTOBER 5, 2020 |
||
| 10:00 | 10:10 | Howard Fillit, MD, Alzheimer’s Drug Discovery Foundation |
| 10:10 | 10:45 | KEYNOTE: Gene Therapy for Neurodegeneration Ronald Crystal, MD, Weill Cornell Medical College |
| 10:45 | 11:00 | POSTER/START-UP SESSION and COFFEE BREAK |
Session I: NOVEL APPROACHES FOR NEUROINFLAMMATIONChair: Lauren Friedman, PhD, Alzheimer's Drug Discovery Foundation |
||
| 11:00 | 11:05 | SESSION OVERVIEW Chair: Lauren Friedman, PhD, Alzheimer's Drug Discovery Foundation |
| 11:05 | 11:20 | Preclinical Development of an Antibody Therapeutic and an Imaging Agent Targeting Fibrin-Mediated Neuroinflammation Jeffrey Stavenhagen, PhD,TheriniBio |
| 11:20 | 11:35 | Phase 1b Study in AD Patients with Neuroinflammation CJ Barnum, PhD, INmune Bio |
| 11:35 | 11:50 | Development of Novel Anti-Neuroinflammatory Small Molecule Drug Candidates Linda Van Eldik, PhD, University of Kentucky |
| 11:50 | 12:05 | Imaging Brain Inflammatory States: Focus on CSF1R Martin Pomper, MD, PhD, Johns Hopkins University |
| 12:05 | 12:15 | SESSION 1: PANEL DISCUSSION |
| 12:15 | 12:30 | POSTER/START-UP SESSION and COFFEE BREAK |
| 12:30 | 13:30 | LUNCH and NETWORKING/POSTERS |
Session II: METABOLIC AND MITOCHONDRIAL APPROACHES FOR ALZHEIMER’S DISEASEChair: Meriel Owen, PhD, Alzheimer's Drug Discovery Foundation |
||
| 13:30 | 13:35 | SESSION OVERVIEW CHAIR: Meriel Owen, PhD, Alzheimer's Drug Discovery Foundation |
| 13:35 | 13:50 | Mitochondrial Epigenetics, a Tool for Alzheimer’s Disease Marta Barrachina, PhD, Admit Therapeutics |
| 13:50 | 14:05 | Benfotiamine in Alzheimer’s Disease: A Pilot Study Gary Gibson, PhD, Burke Neurological Institute |
| 14:05 | 14:20 | Effect of Novel GLP1 Analogue, Liraglutide on Microglial Activation and Cerebral Glucose Metabolism in Mild Alzheimer’s Disease Paul Edison, MD, PhD, Imperial College London |
| 14:20 | 14:30 | SESSION II: PANEL DISCUSSION |
| 14:30 | 14:40 | POSTER/START-UP SESSION and COFFEE BREAK |
Session III: EMERGING AREAS IN DRUG DEVELOPMENT FOR NEURODEGENERATIONChair: Nick McKeehan, Alzheimer's Drug Discovery Foundation |
||
| 14:40 | 14:45 | SESSION OVERVIEW Chair: Nick McKeehan, Alzheimer's Drug Discovery Foundation |
| 14:45 | 15:00 | The Role of Senescent Cells in Alzheimer’s Disease and Dementia Darren Baker, PhD, MS, Mayo Clinic |
| 15:00 | 15:15 | Autophagy in Alzheimer’s Disease and Related Dementias Ralph Nixon, MD, PhD, NYU Langone Health |
| 15:15 | 15:30 | APOE4 Leads to Breakdown in the Blood-brain Barrier Predicting Cognitive Decline Berislav Zlokovic, MD, PhD, Keck School of Medicine, USC |
| 15:30 | 15:45 | Accelerating Therapy Development for Alzheimer’s: from Open Science to Open Drug Discovery Suzana Petanceska, PhD, NIH/NIA |
| 15:45 | 15:55 | SESSION III: PANEL DISCUSSION |
| 15:55 | 16:30 | NETWORKING/POSTERS |
TUESDAY, OCTOBER 6, 2020 |
||
| 10:00 | 10:35 | KEYNOTE: Current State for Blood Biomarkers in AD Henrik Zetterberg, MD, PhD, University of Gothenburg |
Session IV: NEUROPROTECTION, SYNAPTIC HEALTH AND NEUROTRANSMITTERSChair: Alessio Travaglia, PhD, Alzheimer's Drug Discovery Foundation |
||
| 10:35 | 10:40 | SESSION OVERVIEW Chair: Alessio Travaglia, PhD, Alzheimer's Drug Discovery Foundation |
| 10:40 | 10:55 | Novel Positive Allosteric Modulators of the Alpha1A-Adrenergic Receptor to Treat Alzheimer’s Disease Dianne Perez, PhD, CCF |
| 10:55 | 11:10 | In Vivo Characterization of a GABA-A alpha-5 Positive Allosteric Modulator Sharon Rosenzweig-Lipson, PhD, AgeneBio |
| 11:10 | 11:25 | Clinical Trial Results: Glutamate Modulator Riluzole in Patients with Mild Alzheimer’s Disease Ana Pereira, MD, Icahn School of Medicine |
| 11:25 | 11:40 | SESSION IV: PANEL DISCUSSION |
| 11:40 | 12:30 | POSTER/START-UP SESSION and LUNCH BREAK |
| 12:30 | 13:30 | Start-up Forum: GraySpace Therapeutics, Saskatoon, SK, Canada (Tara Smith, PhD) Imaginostics, Inc., Cambridge, MA, US (Codi Gharagouzloo, PhD) NeuroTherapia, Inc., Cleveland, OH, US (Joseph Foss, MD) Optina Diagnotics, Montreal, QC, Canada (Shannon Campbell, PhD) Perha Pharmaceuticals, Roscoff, France (Laurent MEIJER, PhD) TauC3 Biologics Limited, London, United Kingdom (Daniel Chain, PhD) |
Session V: NOVEL BIOMARKERS IN ALZHEIMER’S DISEASEChair: Nicole Bjorklund, PhD, Alzheimer's Drug Discovery Foundation |
||
| 13:30 | 13:35 | SESSION OVERVIEW Chair: Nicole Bjorklund, PhD, Alzheimer's Drug Discovery Foundation |
| 13:35 | 13:50 | Digital Biomarkers in Alzheimer’s Disease Lampros Kourtis, PhD, Circadic |
| 13:50 | 14:05 | High Molecular Weight Kininogen (HKc) as a Diagnostic Tool for Alzheimer’s Disease Sidney Strickland, PhD, The Rockefeller University Erin Norris, PhD, The Rockefeller University |
| 14:05 | 14:20 | TABLOOD: A Biomarker Panel for Direct Assessment in Blood of Alzheimer’s Disease Patho-physiological Hallmarks Douglas Galasko, MD, UCSD |
| 14:20 | 14:35 | Magnetic Susceptibility as a Biomarker for Alzheimer’s Disease Chunlei Liu, PhD, UC Berkeley |
| 14:35 | 14:50 | Circulating Brain-Enriched MicroRNAs as Peripheral Biomarkers of Neurodegeneration Kira Sheinerman, PhD, MBA, DiamiR |
| 14:50 | 15:05 | A Rapid Non-invasive Diagnostic Test to Predict Mild Cognitive Impairment and Early Alzheimer’s Disease Hüseyin Firat, MD, PhD, Amoneta |
| 15:05 | 15:15 | SESSION V: PANEL DISCUSSION |
| 15:15 | 15:20 | CLOSING REMARKS |
| 15:20 | 16:00 | POSTER/START-UP SESSION |
CONFERENCE INTRODUCTION
Monday, October 5, 2020
10:00 US Eastern Time
Howard Fillit
Alzheimer’s Drug Discovery Foundation
Dr. Howard Fillit is ADDF’s Founding Executive Director and Chief Science Officer. His introduction will provide a welcome to our 21st International Conference on Alzheimer’s Drug Discovery, a brief update on ADDF’s recent progress and will highlight the framework for this year’s meeting.
KEYNOTES
Ronald Crystal
Weill Cornell Medical College
Henrik Zetterberg
University of Gothenburg
Gene Therapy for Neurodegeneration
Gene therapy is becoming an area of increasing interest for neurodegenerative diseases. Dr. Crystal is a pioneer in the field of gene therapy having carried out human trials in cystic fibrosis, cardiac ischemia, cancer and CNS disorders. This talk will highlight the challenges of gene therapy approaches for neurodegenerative diseases and potential solutions moving forward for Alzheimer’s disease.
Monday, October 5, 2020
10:10 US Eastern Time
Current State for Blood Biomarkers in AD
Current biomarkers for Alzheimer’s disease are often invasive, expensive and reliant on specialized equipment only available at large clinical research centers. A move towards blood biomarkers could lead to earlier diagnosis, more widely available tests, and streamlined clinical trials. Dr. Zetterberg is a leading expert and driver in this field. His talk will provide an overview of landscape and future directions for blood biomarkers in Alzheimer’s disease.
Tuesday, October 6, 2020
10:00 US Eastern Time
SESSIONS
SESSION I: Novel Approaches for Neuroinflammation
The field continues to learn more about the role that inflammation plays in the progression of Alzheimer’s pathology. This session highlights preclinical drug development, clinical trials and an imaging agent in development to target various aspects of neuroinflammation.
Lauren Friedman
ADDF
CHAIR
Session Overview
Jeffrey Stavenhagen
TheriniBio
CJ Barnum
INmune Bio
Phase 1b Study in AD Patients with Neuroinflammation
Linda Van Eldik
University of Kentucky
Development of Novel Anti-Neuroinflammatory Small Molecule Drug Candidates
Martin Pomper
Johns Hopkins University
Imaging Brain Inflammatory States: Focus on CSF1R
Monday, October 5, 2020
11:00 US Eastern Time
Monday, October 5, 2020
11:05 US Eastern Time
Monday, October 5, 2020
11:20 US Eastern Time
Monday, October 5, 2020
11:35 US Eastern Time
Monday, October 5, 2020
11:50 US Eastern Time
PANEL DISCUSSION – SESSION I
Monday, October 5, 2020
12:05 – 12:15 US Eastern Time
POSTER SESSION/BREAK
This session will feature research from early investigators in the academic community focused on drug development for Alzheimer’s and related dementias.
Monday, October 5, 2020
12:15 – 12:30 US Eastern Time
LUNCH/NETWORKING/POSTERS
Monday, October 5, 2020
12:30 – 13:30 US Eastern Time
SESSION II: Metabolic and Mitochondrial Approaches for Alzheimer’s Disease
Mounting evidence suggests that energy dysregulation in the form of metabolic or mitochondrial changes can contribute to the progression of Alzheimer’s disease. This session features a company developing innovative new drugs targeting mitochondria and the presentation of two completed clinical trials in the space.
Meriel Owen
ADDF
CHAIR
Session Overview
Marta Barrachina
Admit Therapeutics
Gary Gibson
Burke Neurological Inst.
Benfotiamine in Alzheimer’s Disease: A Pilot Study
Paul Edison
ICL
Effect of Novel GLP1 Analogue, Liraglutide on Microglial Activation and Cerebral Glucose Metabolism in Mild Alzheimer’s Disease
Monday, October 5, 2020
13:30 US Eastern Time
Monday, October 5, 2020
13:35 US Eastern Time
Monday, October 5, 2020
13:50 US Eastern Time
Monday, October 5, 2020
14:05 US Eastern Time
PANEL DISCUSSION – SESSION II
Monday, October 5, 2020
14:20 – 14:30 US Eastern Time
POSTER SESSION/BREAK
Monday, October 5, 2020
14:30 – 14:40 US Eastern Time
SESSION III: Emerging Areas in Drug Development for Neurodegeneration
The ADDF closely follows emerging areas of aging biology that could be targeted to halt, prevent and cure Alzheimer’s and related dementias. This session will feature overviews of some of these promising areas which include cellular senescence, autophagy and vascular contributions to dementia.
Nick McKeehan
ADDF
CHAIR
Session Overview
Darren Baker
Mayo Clinic
Ralph Nixon
NS Kline Inst.
Berislav Zlokovic
USC
Suzana Petanceska
NIH/NIA
Accelerating Therapy Development for Alzheimer’s: from Open Science to Open Drug Discovery
Monday, October 5, 2020
14:40 US Eastern Time
Monday, October 5, 2020
14:45 US Eastern Time
Monday, October 5, 2020
15:00 US Eastern Time
Monday, October 5, 2020
15:15 US Eastern Time
Monday, October 5, 2020
15:30 US Eastern Time
PANEL DISCUSSION – SESSION III
Monday, October 5, 2020
15:45 – 15:55 US Eastern Time
POSTER SESSION/BREAK
Monday, October 5, 2020
15:55 – 16:30 US Eastern Time
SESSION IV: Neuroprotection, Synaptic Health and Neurotransmitters
Synaptic and neuronal degeneration have been linked to the cognitive decline experienced in Alzheimer’s and related dementias. This session underscores the innovative work in neuroprotection featuring new progress from companies and in academic labs as well as the results from two completed clinical trials.
Alessio Travaglia
ADDF
CHAIR
Session Overview
Dianne Perez
CCF
Novel Positive Allosteric Modulators of the Alpha1A-Adrenergic Receptor to Treat Alzheimer’s Disease
Sharon Rosenzweig-Lipson
AgeneBio
In Vivo Characterization of a GABA-A alpha-5 Positive Allosteric Modulator
Ana Pereira
ISMMS
Clinical Trial Results: Glutamate Modulator Riluzole in Patients with Mild Alzheimer’s Disease
Tuesday, October 6, 2020
10:35 US Eastern Time
Tuesday, October 6, 2020
10:40 US Eastern Time
Tuesday, October 6, 2020
10:55 US Eastern Time
Tuesday, October 6, 2020
11:10 US Eastern Time
PANEL DISCUSSION – SESSION IV
Tuesday, October 6, 2020
11:40 – 11:50 US Eastern Time
LUNCH and POSTERS
Tuesday, October 6, 2020
11:50 – 12:30 US Eastern Time
SESSION V: START-UP FORUM
This session will feature drug development programs being pursued by start-up companies.
Tuesday, October 6, 2020
12:30 – 13:30 US Eastern Time
SESSION VI: Novel Biomarkers in Alzheimer’s Disease
Biomarkers play an important role in many aspects of clinical care and development including diagnosis, prognosis, clinical trial enrollment, enrichment, monitoring and outcomes. This session will feature some of the most promising emerging fluid, digital and imaging biomarkers in development for Alzheimer’s disease.
Nicole Bjorklund
ADDF
CHAIR
Session Overview
Lampros Kourtis
Circadic
Digital Biomarkers in Alzheimer’s Disease
Sidney Strickland
The Rockefeller Univ.
High Molecular Weight Kininogen (HKc) as a Diagnostic Tool for Alzheimer’s Disease
Douglas Galasko
UC San Diego
TABLOOD: A Biomarker Panel for Direct Assessment in Blood of Alzheimer’s Disease Patho-physiological Hallmarks
Chunlei Liu
UC Berkeley
Magnetic Susceptibility as a Biomarker for Alzheimer’s Disease
Tuesday, October 6, 2020
13:30 US Eastern Time
Tuesday, October 6, 2020
13:35 US Eastern Time
Tuesday, October 6, 2020
13:50 US Eastern Time
Tuesday, October 6, 2020
14:05 US Eastern Time
Tuesday, October 6, 2020
14:20 US Eastern Time
Kira Sheinerman
DiamiR Biosciences
Circulating Brain-Enriched MicroRNAs as Peripheral Biomarkers of Neurodegeneration
Hüseyin Firat
Amoneta
A Rapid Non-invasive Diagnostic Test to Predict Mild Cognitive Impairment and Early Alzheimer’s Disease
Tuesday, October 6, 2020
14:35 US Eastern Time
Tuesday, October 6, 2020
14:50 US Eastern Time
PANEL DISCUSSION – SESSION VI
Tuesday, October 6, 2020
15:05 – 15:15 US Eastern Time
CONCLUSIONS
Tuesday, October 6, 2020
15:15 – 15:20 US Eastern Time
NETWORKING/POSTERS
Tuesday, October 6, 2020
15:20 – 16:00 US Eastern Time